Vormatrigine for adults with focal seizures
Official title: A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
Run by Praxis Precision Medicines · NCT07505004 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This trial will try daily vormatrigine at three different doses versus placebo in adults with focal seizures to see if it reduces seizure frequency and is safe.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Praxis Precision Medicines Industry-sponsored |
| Locations | 7 sites (Miami, Florida and 6 other locations) |
| Trial ID | NCT07505004 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with focal onset epilepsy who are on 1–3 stable anti-seizure medications, have at least four countable focal seizures during a 4‑week baseline, and can maintain a seizure diary are ideal candidates.
✕Probably not a fit
People with progressive structural causes of epilepsy, documented psychogenic non-epileptic seizures, unclear or uncountable cluster seizures, unstable ASM regimens, or who cannot meet diary or visit requirements are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial testing three fixed daily doses of vormatrigine (20, 30, 40 mg) taken for 12 weeks compared with placebo. Adults must have focal onset epilepsy, be on 1–3 stable anti-seizure medications, and document at least four countable focal seizures during a 4‑week baseline observation with good diary adherence. Participants are randomized to one of the active dose groups or placebo and followed for seizure frequency and safety outcomes. The primary focus is on seizure reduction and tolerability across the treatment period.
Why it matters
Potential benefit: If successful, vormatrigine could offer an additional oral treatment option that reduces seizure frequency and improves seizure control for adults with focal epilepsy.
How similar studies have gone: Earlier-phase trials of vormatrigine showed enough promise to advance to this Phase 3 program, but definitive large-scale Phase 3 results are not yet available.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017). * Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor. * Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1. * Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period. * Seizure diary must be completed for ≥80% days in the Observation Period. Exclusion Criteria: * Participant has had any of the following within the 12-month period preceding trial entry: 1. evidence of experiencing pseudo or psychogenic seizures 2. cluster seizures where the individual seizures cannot be counted 3. an episode of convulsive status epilepticus requiring hospitalization and intubation 4. seizures secondary to illicit drug or alcohol use * Seizures secondary to ongoing infection, neoplasia, demyelinating disease, progressive degenerative disease, metabolic illness deemed progressive, progressive structural lesion or encephalopathy. * Previously documented EEG which shows any pattern not consistent with focal etiology of seizures. * Planned epilepsy surgery during the course of the clinical trial. * History of any of the following: 1. neurosurgery for seizures \<1 year prior to enrollment 2. radiosurgery \<2 years prior to enrollment 3. neurostimulator placed \<1 year prior to Screening 4. neurostimulator placed \>1 year prior to Screening but settings have not been stable for at least 2 months prior to Screening * Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt, as confirmed by C-SSRS. * Has any significant ongoing disease, disorder, laboratory abnormalities, alcohol or drug abuse or dependence, environmental factor, or ongoing or recent history of any psychiatric, medical, or surgical condition. * Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 3 years are excluded. * History or presence of uncontrolled cardiac diseases including conduction and structural abnormalities. * Total bilirubin value \>1.5×ULN; an ALT or AST value \>3×ULN. * History of or active HIV infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active hepatitis B or hepatitis C infection, as determined by relevant screening assessments. * Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene or cell therapy. * Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin. * Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to screening. * Significant allergic reaction to an ASM(s), including dermatological (e.g. Stevens-Johnson syndrome), hematological, or organ toxicity reactions. Severe reactions do not include simple maculopapular eruption and allergic rhinitis. * Is pregnant or breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or prior to end of study visit. * Previous exposure to vormatrigine or known hypersensitivity to any component used in the vormatrigine formulation.
Where it's running
-
Praxis Research Site
Miami, Florida, United States Recruiting -
Praxis Research Site
Miami Lakes, Florida, United States Recruiting -
Praxis Research Site
Marlboro, New Jersey, United States Recruiting -
Praxis Research Site
Niagara Falls, New York, United States Recruiting -
Praxis Research Site
Raleigh, North Carolina, United States Recruiting -
Praxis Research Site
Houston, Texas, United States Recruiting
Show 1 more location
-
Praxis Research Site
Naples, Florida, United States Not yet recruiting
Study contacts
- Study coordinator: Senior Medical Director Clinical Development
- Email: clinicaltrials@praxismedicines.com
- Phone: 773-939-6858
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-density flexible microneuroelectrode mapping to guide epilepsy surgery
This study tests whether using high-density flexible microelectrocorticography during surgery helps guide the resection of the epileptogenic zone in people with drug-resistant focal epilepsy.
-
RAP-219 for adults with focal seizures
This study tests whether RAP-219 can reduce how often focal seizures happen in adults with focal epilepsy, compared with a placebo.
-
Spatial scene memory testing for people with temporal lobe epilepsy having surgery
This project tests whether a virtual tour memory task combined with brain recordings can show how adults with temporal lobe epilepsy recognize and recall places.
-
RAP-219 in adults with focal seizures
This study tests whether RAP-219 can safely reduce the number of focal seizures in adults with focal epilepsy compared with placebo.
-
Probenecid for cluster seizures during presurgical epilepsy monitoring
This trial tests whether probenecid can help control clusters of seizures in people with focal epilepsy during presurgical video-EEG monitoring.
-
Long-term daily CB03-154 treatment for focal epilepsy
This extension will try once-daily CB03-154 (up to 20 mg) in people with focal epilepsy who completed the prior Phase 2 study to see if it is safe, tolerated, and helps control seizures over up to two years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.